Targeted Systemic Exposure for Pediatric Cancer Therapy

1991 ◽  
pp. 177-183 ◽  
Author(s):  
John H. Rodman ◽  
William E. Evans
Keyword(s):  
Cancer Therapy ◽  
Pediatric Cancer ◽  
Systemic Exposure

Late and Acute Effects of Pediatric Cancer Therapy on the Oral Cavity

2013 ◽  
pp. 321-330
Author(s):  
Christopher Rowland ◽  
Cesar A. Migliorati ◽  
Sue C. Kaste
Keyword(s):  
Cancer Therapy ◽  
Oral Cavity ◽  
Pediatric Cancer ◽  
Acute Effects

Pediatric cancer therapy and fertility

2011 ◽  
pp. 73-82
Author(s):  
Pinki K. Prasad ◽  
Jill Simmons ◽  
Debra Friedman
Keyword(s):  
Cancer Therapy ◽  
Pediatric Cancer

Pediatric Cancer Therapy

1981 ◽  
Vol 3 (2) ◽  
pp. 221 ◽  
Author(s):  
C. Philip Steuber
Keyword(s):  
Cancer Therapy ◽  
Pediatric Cancer

Parents’ understanding of the risk of late effects of pediatric cancer therapy.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. 10522-10522 ◽  
Author(s):  
Katie Greenzang ◽  
Angel Cronin ◽  
Tammy I Kang ◽  
Jennifer W. Mack
Keyword(s):  
Cancer Therapy ◽  
Pediatric Cancer ◽  
Late Effects

scholarly journals Biomaterial implants in the treatment of oncology: a review

2021 ◽  
Vol 10 (7) ◽  
pp. 886
Author(s):  
Saba Maanvizhi ◽  
Vijayakumar Arumugam Ramamurthy ◽  
Athithan Velan ◽  
Pugazhenthan Thangaraju
Keyword(s):  
Cancer Therapy ◽  
Sebacic Acid ◽  
Systemic Exposure ◽  
Local Therapy ◽  
Local Delivery ◽  
Tumor Site ◽  
Organ Toxicity ◽  
Micro Particles ◽  
Acid Copolymer ◽  
Different Types

In globally, cancer is a second leading disease next to cardiovascular diseases in non-communicable diseases, which affect the all ages, sex, social status, ethnicity and primary cause of illness related death. Traditionally, systemic delivery drug systems like chemotherapy via oral capsule, injections of nanoparticles/micro particles, immunotherapy and others, which can inhibit or halt the progression of tumors. The short half-life of drugs which cannot achieve the targeted dose level to the tumor site and not able to target desired cell and commonly produces the organ toxicity. Recently, researchers have been attempting to direct delivery agents for cancer therapy. One of the best methods is a local therapy system, which deliver the drug directly via implantable procedure and it’s achieved the maximum concentration of the desire drug at the tumor site, non-target systemic exposure and minimize the organ toxicity to the patients. Biomaterial implants are widely used in the local concurrent delivery of chemotherapy and anti-angiogenic agents, local delivery of poly-chemotherapy, gene therapy as an alternative to drug delivery, scaffolds for cancer immunotherapy and polymer-based composites of drug molecules. There are different types of polymers like poly anhydride poly [bis (p-carboxy-phenoxy) propane-sebacic acid] copolymer [p(CPP:SA)], fatty acid dimer-sebacic acid copolymer (FAD-SA), poly (lactic-co-glycolic acid) copolymer (PLGA), poly (ε-caprolactone) (PCL), poly (glycerol monostearate-co-caprolactone), alginate and silica, used in successively cancer therapy. In order to minimize the risk of unwanted side effect of different types of biomaterials implants, it’s biocompatible to reduce the ability to elicit the inflammatory effect to the implanted area or the site. Therefore, the key role of choosing the appropriate and biocompatible implants to particular therapy is an indispensable. This should be validated with respect to risk benefit ratio in case of cancers. Biomaterial based implant local delivery systems provide more versatile and tailorable approach to against treatment of different types of the cancer.

PEDIATRIC CANCER THERAPY

1980 ◽  
Vol 9 (12) ◽  
pp. 62-63
Author(s):  
Donald J Fernbach
Keyword(s):  
Cancer Therapy ◽  
Pediatric Cancer

scholarly journals Hyperglycemia During Childhood Cancer Therapy: Incidence, Implications, and Impact on Outcomes

2019 ◽  
Vol 2019 (54) ◽  
pp. 132-138 ◽  
Author(s):  
Allison Grimes ◽  
Ashraf Mohamed ◽  
Jenna Sopfe ◽  
Rachel Hill ◽  
Jane Lynch
Keyword(s):  
Risk Factors ◽  
Cancer Therapy ◽  
Adverse Effects ◽  
Cancer Treatment ◽  
Childhood Cancer ◽  
Pediatric Cancer ◽  
Immune Checkpoint Inhibitors ◽  
Systematic Approach ◽  
Checkpoint Inhibitors ◽  
Limited Data

Abstract Hyperglycemia is a known complication of therapies used in the treatment of childhood cancer, particularly glucocorticoids and asparaginase. It has been linked to increased infection and reduced survival. With more limited data on hyperglycemia during childhood cancer treatment compared with adult cancer, impact on outcomes is less clear in this population. As additional glycemic-altering cancer agents including immune checkpoint inhibitors and targeted therapies make their way into pediatric cancer treatment, there is a more pressing need to better understand the mechanisms, risk factors, and adverse effects of hyperglycemia on the child with cancer. Thus, we utilized a systematic approach to review the current understanding of the incidence, implications, and outcomes of hyperglycemia during childhood cancer therapy.

Sign in / Sign up

Export Citation Format

Share Document